

Thomas Jefferson University Jefferson Digital Commons

Kimmel Cancer Center Papers, Presentations, and Grand Rounds

Kimmel Cancer Center

5-3-2024

Oncology Treatment Plan Updates in EPIC-Beacon

Rose DiMarco, PharmD, BCPS, BCOP Thomas Jefferson University

Gloria Espinosa, MAT, PharmD, BCOP Thomas Jefferson University

Kelly Miskovsky, PharmD, BCOP Thomas Jefferson University

Gina Hemmert, PharmD

Thomas Jefferson University

Follow this and additional works at: https://jdc.jefferson.edu/kimmelgrandrounds

Part of the Oncology Commons, and the Pharmacy and Pharmaceutical Sciences Commons

Let us know how access to this document benefits you

Recommended Citation

DiMarco, PharmD, BCPS, BCOP, Rose; Espinosa, MAT, PharmD, BCOP, Gloria; Miskovsky, PharmD, BCOP, Kelly; and Hemmert, PharmD, Gina, "Oncology Treatment Plan Updates in EPIC-Beacon" (2024). *Kimmel Cancer Center Papers, Presentations, and Grand Rounds*. Paper 71. https://jdc.jefferson.edu/kimmelgrandrounds/71

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Kimmel Cancer Center Papers, Presentations, and Grand Rounds by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.



Oncology Treatment Plan Updates in EPIC-Beacon

Rose DiMarco, PharmD, BCPS, BCOP, Gloria Espinosa, MAT, PharmD, BCOP, Kelly Miskovsky, PharmD, BCOP, Gina Hemmert, PharmD

Thomas Jefferson University Hospital Department of Oncology Pharmacy, EPIC-Beacon

Background

In Medical Oncology, the utilization of EPIC-Beacon Treatment Plans is integral for prescribing and administering cancer treatments. These treatment plans typically consist of anticancer infusion medications (chemotherapy, immunotherapy, etc.), supportive care medications, required laboratory orders, and other monitoring recommendations to ensure that patients receive safe and effective care. In 2017, TJUH transitioned from Varian's Aria to EPIC's electronic medical record system. Since then, there has not been a formal review of existing plans, and there are many inconsistencies between plans in different cancer types.

Problem Statement:

• Currently, there is not a formal process for review of existing treatment plans, and standardization efforts have been limited.

Project Aim:

• Establish standardized guidelines for all components of the EPIC-Beacon Treatment plans, perform a review of all standard-of-care EPIC-Beacon Treatment plans, and develop a process for future review.

Baseline Metrics

At the start of this project, nearly 1000 EPIC-Beacon plans were built and available for ordering.

- Inclusion Criteria: Standard of care and research plans if the treatment was considered standard of care and antiemetic premedications needed to be updated.
- Exclusion Criteria: Plans containing only oral anticancer medications, intrathecal medications, urology bladder instillations, interventional radiology treatments, and research plans without standard of care treatments.


Cancer Type	Approximate # of Plans (including Research)			
BMT/CAR-T Therapy	46			
Breast Cancer	115			
CNS Cancer	21			
Gastrointestinal Cancer	168			
Genitourinary Cancer	76			
Gynecologic Cancer	92			
Head & Neck/Thyroid Cancer	47			
Leukemia	112			
Lung Cancer	75			
Lymphoma	126			
Melanoma	53			
Multiple Myeloma	59			
Sarcoma	46			
BMT: bone marrow transplant; CAR-T: chimeric antigen receptor T-cell; CNS: central nervous system				

Interventions

Phase 1:

• The Department of Oncology Pharmacy began with a review of every FDA-approved formulary anticancer medication package insert to ensure that drug-specific recommendations for safety and monitoring were included in each treatment plan.

Guidelines and Recommendations Developed for this Project



Phase 2:

 Oncology Pharmacy reviewed each treatment plan and complied of list of updates based on the package inserts, guidelines, and recommendations as listed above.

Cancer Type	Plans Reviewed	Plans Updated (%)	Average # Interventions Per Plan
Breast Cancer	110	90 (82)	2.47
Gastrointestinal Cancer	130	92 (71)	1.66
Genitourinary Cancer	73	70 (96)	2.44
Melanoma	19	18 (95)	2.2
Sarcoma	43	41 (95)	3.07

Challenges and Lessons Learned

- The Jefferson Health Enterprise has grown to include 7 different infusion sites, which complicates alignment and standardization efforts.
- Each phase of this project has taken significant time, and new plans were built while others were in review or being updated leading to increased turnaround times.
- Due to the number of updates and the need for insurance authorization with any treatment plan changes, it has not been possible to update plans for active patients, which has led to some confusion in the infusion center.
- Staffing challenges are a major barrier to quality improvement projects, especially at such a large scale.
- Interdisciplinary collaboration is key provider and nursing input throughout this project has been crucial.

Future Directions

- Continued review and update of remaining solid tumor and hematologic malignancies plans.
- Develop a plan for annual review of all updated plans.
- Consider a similar project for the oral anti-cancer medication treatment plans.

Linkage to Healthcare Disparities

The EPIC-Beacon Treatment Plans are used to prescribe cancer treatments to patients across the Jefferson Health Enterprise. Jefferson Health currently utilizes Oncology Pathways to support decision-making throughout the chemotherapy ordering process. This project represents the next step in alignment across the Enterprise. Standardization allows all patients to receive the same quality, guideline-directed care at each Jefferson Health site. Developing a mechanism for annual review and updates will also ensure that Jefferson Health patients continue to receive excellent care that reflects national best practice guidelines.

@ResearchAtJeff